Use of Yttrium-90 Microspheres in the Treatment of Unresectable Hepatic Metastases From Breast Cancer

International Journal of Radiation Oncology Biology Physics

Volumn 69, Issue 3, 2007, Pages 800-804

  Coldwell, Douglas M ^a   Kennedy, Andrew S ^b   Nutting, Charles W ^c  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

^b Wake Radiology Oncology   (United States)

^c Sky Ridge Medical Center   (United States)

Author keywords

Brachytherapy; Breast; Liver; Microsphere; Yttrium

Indexed keywords

DOSIMETRY; ONCOLOGY; PATIENT TREATMENT; TOXICITY; TUMORS; YTTRIUM;

BRACHYTHERAPY; HEPATIC ARTERIAL VESSELS; LIVER METASTASES; RADIOACTIVE MICROSPHERES;

MICROSPHERES;

DOCETAXEL; DOXORUBICIN; FLUORODEOXYGLUCOSE; MICROSPHERE; TRASTUZUMAB; YTTRIUM 90;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DEATH; DRUG FEVER; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; LIVER METASTASIS; LIVER TUMOR; LIVER VENOOCCLUSIVE DISEASE; NAUSEA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TREATMENT RESPONSE; UPPER QUADRANT PAIN; VASCULAR ACCESS; VOMITING;

ADULT; AGED; BRACHYTHERAPY; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MICROSPHERES; MIDDLE AGED; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; YTTRIUM RADIOISOTOPES;

EID: 34548676165     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2007.03.056     Document Type: Article

References (28)

1. Jemal A., Murray T., Ward E., et al. Cancer statistics, 2005. CA Cancer J Clin 55 (2005) 10-30
2. Viadana E., Bross I.D.J., and Pickren J.W. An autopsy study of some routes of dissemination of cancer of the breast. Br J Cancer 27 (1973) 336
3. Goldberg R.M., and Gill S. Recent phase III trials of fluorouracil, irinotecan, and oxaliplatin as chemotherapy for metastatic colorectal cancer. Cancer Chemother Pharmacol 54 Suppl. 1 (2004) S57-S64
4. Goldberg R.M., Sargent D.J., Morton R.F., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
5. Grothey A., Sargent D., Goldberg R.M., et al. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22 (2004) 1209-1214
6. Kato I., Severson R.K., and Schwartz A.G. Conditional median survival of patients with advanced carcinoma: Surveillance, Epidemiology, and End Results data. Cancer 92 (2001) 2211-2219
7. Gray B.N., Anderson J.E., Burton M.A., et al. Regression of liver metastases following treatment with yttrium-90 microspheres. Aust N Z J Surg 62 (1992) 105-110
8. Stubbs R.S., Cannan R.J., and Mitchell A.W. Selective internal radiation therapy (SIRT) with 90Yttrium microspheres for extensive colorectal liver metastases. Hepato-Gastroenterology 48 (2001) 333-337
9. Lau W.Y., Leung W.T., Ho S., et al. Treatment of inoperable hepatocellular carcinoma with intrahepatic arterial yttrium-90 microspheres: A phase I and II study. Br J Cancer 70 (1994) 994-999
10. 90yttrium microspheres. Int J Radiat Oncol Biol Phys 40 (1998) 583-592
11. Kennedy A.S., Murthy R., Sarfaraz M., et al. Outpatient hepatic artery brachytherapy for primary and secondary hepatic malignancies. Radiology 221P (2001) 468
12. Kennedy A.S., Murthy R., and Van Echo D.A. Preliminary results of outpatient hepatic artery brachytherapy for colorectal hepatic metastases. Eur J Cancer 37 (2001) 289
13. Van Echo D.A., Kennedy A.S., and Coldwell D. TheraSphere (TS) at 143 Gy median dose for mixed hepatic cancers; feasibility and toxicities. Am Soc Clin Oncol 260a (2001) 1038
14. Coldwell D., Kennedy A.S., Van Echo D.A., et al. Feasibility of treatment of hepatic tumors utilizing embolization with yttrium-90 glass microspheres. J Vasc Interv Radiol 12 (2001) S113
15. Andrews J.C., Walker S.C., Ackermann R.J., et al. Hepatic radioembolization with yttrium-90 containing glass microspheres: Preliminary results and clinical follow-up. J Nucl Med 35 (1994) 1637-1644
16. Dancey J.E., Shepherd F.A., Paul K., et al. Treatment of nonresectable hepatocellular carcinoma with intrahepatic 90Y microspheres. [in process citation]. J Nucl Med 41 (2000) 1673-1681
17. Murthy R., Kennedy A.S., Coldwell D., et al. Technical aspects of TheraSphere (TS) infusion. J Vasc Interv Radiol 13 (2002) S2
18. Murthy R., Kennedy A.S., Tucker G., et al. Outpatient trans arterial hepatic 'low dose rate' (TAH-LDR) brachytherapy for unresectable hepatocellular carcinoma. Proc Am Assoc Cancer Res 43 (2002) 485
19. Murthy R., Line B.R., Kennedy A.S., et al. Clinical utility of Brehmstralung scan (BRM-Scan) after TheraSphere (TS). J Vasc Interv Radiol 13 (2002) S2
20. 90Y microsphere brachytherapy for unresectable colorectal liver metastases: Modern USA experience. Int J Radiat Oncol Biol Phys 65 (2006) 412
21. Coldwell D.M., and Sewell P.E. The expanding role of interventional radiology in the supportive care of the oncology patient: From diagnosis to therapy. Semin Oncol 32 (2005) 169-173
22. Cancer Therapy Evaluation Program. December 12, 2003. Available at: http://ctep.cancer.gov. Accessed February 1, 2007.
23. Nemato T., and Dao T.L. Significance of liver metastases in women with disseminated breast cancer undergoing endocrine ablative surgery. Cancer 19 (1966) 421
24. Jardines L., Callans L.S., and Torosian M.H. Recurrent breast cancer: Presentation, diagnosis, and treatment. Semin Oncol 20 (1993) 538-547
25. Pentheroudakis G., Fountzilas G., Bafaloukos D., et al. Metastatic breast cancer with liver metastases: A registry analysis of clinicopathologic, management and outcome characteristics of 500 women. Breast Cancer Res Treatment 97 (2005) 237-244
26. Eichbaum M.H.R., Kaltwasser M., Bruckner T., et al. Prognostic factors for patients with liver metastases from breast cancer. Breast Cancer Res Treat 96 (2006) 53-62
27. Elias D., Maisonnette F., Druet-Cabanac M., et al. An attempt to clarify indications for hepatectomy for liver metastases from breast cancer. Am J Surg 185 (2003) 158-164
28. Vlastos G., Smith D.L., Singletary E., et al. Long-term survival after an aggressive surgical approach in patients with breast cancer hepatic metastases. Ann Surg Oncol 11 (2004) 869-874